This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Ayurvedic Herbs in Diarrhea Predominant Irritable Bowel Syndrome (AHIB)

This study has been completed.
Information provided by (Responsible Party):
Jost Langhorst, Universität Duisburg-Essen Identifier:
First received: August 15, 2011
Last updated: December 5, 2012
Last verified: December 2012
In the present study the investigators are trying to evaluate the effect of Murraya koenigii leaves, Punica granatum and Curcuma which is administered to the patients in a combined form as tea. This study will help to evaluate the effect of these preparations scientifically in improving the IBS symptoms.

Condition Intervention
Irritable Bowel Syndrome Drug: Ayurvedic Herbs Drug: Placebo tea

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Feasibility and Safety of Ayurvedic Herbs in Diarrhoea-predominant Irritable Bowel Syndrome

Resource links provided by NLM:

Further study details as provided by Jost Langhorst, Universität Duisburg-Essen:

Primary Outcome Measures:
  • irritable bowel syndrome- symptom severity score [ Time Frame: T2 (Day 28) ]
    IBS-SSS(Francis, 1997)

Secondary Outcome Measures:
  • Frequency of abdominal discomfort/Pain [ Time Frame: last week of treatment (days 21-28) ]
    Diary, daily rating of pain

  • Intensity of Abdominal Pain/Discomfort [ Time Frame: Last week of treatment (days 21-28) ]
    Diary, daily rating of pain on a 100mm Visual Analog Scale

  • Stool and diarrhea Frequency [ Time Frame: last week of treatment (days 21-28) ]
    Diary, daily counts

  • Quality of life [ Time Frame: T2 (Day 28) ]
    measured with the EQ-5D

  • IBS Specific Quality of life [ Time Frame: T2 (Day 28) ]
    measured with the IBS-QOL (Patrick, 1998)

  • Depression and Anxiety [ Time Frame: T2 (day 28) ]
    HADS questionnaire (Hermann, 1995)

  • Adequate Relief Score [ Time Frame: at day 7, 14, 21 and 28 ]
    Adequate Relief Score (Mangel, 1998)

  • Global improvement [ Time Frame: at days 7, 14, 21 and 28 ]
    Question on global improvement: How have your symptomes changed compared to the last week: from much worse to much better on a 7-point scale

  • adverse events [ Time Frame: up to week 15 ]
    all adverse events

Enrollment: 32
Study Start Date: August 2011
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Tea decoction made of Graminis Flores abd Maidis stigmata.
Drug: Placebo tea
Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
Other Name: n.a.
Experimental: Ayurvedic herbs
Tea decoction made of Murraya koenigii leaves, Punica granatum and Curcuma
Drug: Ayurvedic Herbs
A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
Other Name: n.a.

Detailed Description:
see above

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Irritable Bowel Syndrome according to Rom-III
  • Subtype Diarrhea or Alternating
  • discomfort or pain > 1 times a week
  • discomfort or pain > 4 on a Visual Analog Scale

Exclusion Criteria:

  • Inflammatory bowel diseases (test results necessary)
  • Lactose, Fructose Malabsorption (test results necessary)
  • Celiac Disease
  • Pregnancy or Breastfeeding
  • Colectomy or Hemicolectomy >50cm
  • Severe metabolic disorders, hormonal disorders, cardiac or respiratory failure, liver or renal diseases
  • severe depression, psychotic or psychiatric disorders, substance abuse
  • cancer within the last 5 years
  • allergy to caraway
  • acute inflammatory diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01418066

Klinik für Naturheilkunde und Integrative Medizin
Essen, NRW, Germany, 45276
Sponsors and Collaborators
Universität Duisburg-Essen
Principal Investigator: Jost Langhorst, Prof., MD University Duisburg-Essen, Chair of Integrative Gastroenterology
  More Information

Responsible Party: Jost Langhorst, Prof. Dr., Universität Duisburg-Essen Identifier: NCT01418066     History of Changes
Other Study ID Numbers: 11-4673 AHIB
Study First Received: August 15, 2011
Last Updated: December 5, 2012

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Pathologic Processes
Signs and Symptoms, Digestive
Signs and Symptoms
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases processed this record on August 18, 2017